Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's mission is to deliver potentially best-in-class therapies to transform the treatment of these conditions. Dianthus Therapeutics maintains co-located corporate headquarters in New York, NY, and Waltham, MA.

The company's pipeline includes its lead antibody, claseprubart (DNTH103), which is engineered for extended half-life, improved potency, and high selectivity for the active C1s complement protein. This design aims to enable less frequent, self-administered subcutaneous injections for patients. Claseprubart is being developed for conditions such as generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN), and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Dianthus also has DNTH212, a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation, in its clinical pipeline.

Dianthus Therapeutics became a publicly traded company via a reverse merger with Magenta Therapeutics, Inc. on September 11, 2023, with Magenta Therapeutics subsequently being renamed Dianthus Therapeutics, Inc. Recent developments include an early "go" decision for claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) program, based on interim responder analysis results from the Phase 3 CAPTIVATE trial. Marino Garcia serves as the President, Chief Executive Officer, and a Director of the company.